2023
Strong Rise in Revenue Despite Medicare Uncertainty
Pacific Edge today reports strong growth in operating revenue in the half year to the end of September - up 50% to $13.1 million from $8.7 million in the same period a year ago - as it benefited from growing demand for its suite of Cxbladder tests. [read more]
Kaiser Permanente EMR Integration Goes Live
Pacific Edge announces the launch of the integration of Cxbladder tests within the Electronic Medical Records (EMR) system of Kaiser Permanente. [read more]
Published economic model demonstrates significant savings for healthcare payers
A budget impact model showing routine use of Cxbladder Detect delivers significant savings in the evaluation and treatment of hematuria patients is now published in Urology Practice. [read more]
Cxbladder Test Volumes Resilient in the Face of Headwinds
Pacific Edge today announces test volumes processed at its laboratories in the second quarter of the 2024 financial year (Q2 24) fell 12% to 8,525 from 9,704 in the prior quarter (Q1 24) amid the reorganization of our US operations and publicity on the Medicare coverage determinations. [read more]
FDA Signals intent to Regulate Lab Developed Tests
Pacific Edge notes the U.S. Food and Drug Administration (FDA) has released for public comment proposed rule changes that seek to have Laboratory Developed Tests (LDTs) such as Cxbladder regulated as medical devices under the US Federal Food, Drug, and Cosmetic Act. [read more]
Pacific Edge Releases Submissions on Medicare LCD
Pacific Edge today releases details of written submissions on the draft local coverage determination (LCD) that proposes non-coverage of Cxbladder tests by Medicare, the US national health insurance provider. [read more]
US Urological Societies Call for Medicare LCD Revision
Pacific Edge welcomes the strong industry and clinician support it has received during the open public meetings to take feedback on draft local coverage determinations (LCDs) that propose non-coverage of Cxbladder tests by Medicare, the US national health insurance provider. [read more]
Novitas Releases New Draft LCD
Pacific Edge notes the release overnight of a new proposed Local Coverage Determination (LCD) governing the reimbursement of its Cxbladder tests by Medicare, the US National Health Insurance provider. [read more]
Pacific Edge 2023 Annual Shareholder Meeting
Pacific Edge today held its Annual Shareholders Meeting at LINK Market Services' offices in Auckland. [read more]
Q1 24 Investor Update – Test Volumes Reach New Heights
Pacific Edge has today released its Shareholder Update showing test volumes processed in its laboratories rising to a new record in the first quarter of the 2024 financial year (Q1 24) of 9,706. The figure represents a 9% rise on the 8,877 tests in the prior quarter (Q4 23). [read more]
Pacific Edge Welcomes Stay of Novitas LCD
Pacific Edge today welcomes a decision from Novitas and First Coast to delay the implementation of the Local Coverage Determination (LCD, L35396) released in early June that would have seen Medicare coverage of Cxbladder cease in the US on 17 July 2023. [read more]
Pacific Edge Updates Billing Policies for US Testing
Pacific Edge today announces an update to its billing policies in the US for Cxbladder tests. [read more]
Notice of Annual Shareholders Meeting
Notice is hereby given that the 2023 Annual Shareholders’ Meeting of Pacific Edge Limited will be held at Link Market Services Board Room, Level 30, PwC Tower, 15 Customs Street West, in Auckland and online on Thursday 27 July, commencing at 10.00am. [read more]
Pacific Edge Annual Report
Pacific Edge is pleased to present its Annual Report for the year to 31 March 2023. [read more]
Medicare Coverage of Cxbladder Expected to Cease
Pacific Edge today announces Medicare coverage of Cxbladder tests in the US market is expected to cease from 17 July 2023. [read more]
Pacific Edge Trading Halt
Pacific Edge has applied for and been granted a trading halt over its shares on the NZX and ASX. [read more]
Clarification of Novitas Timeline
Pacific Edge today wishes to clarify the expected timeline for the finalization or withdrawal of the draft Local Coverage Determination (LCD) and the associated Local Coverage Article (LCA) covering the reimbursement of its Cxbladder tests by Medicare. [read more]
Pacific Edge Delivers on Growth Strategy in FY 2023
Pacific Edge today announces financial and operational results for the year to 31 March 2023 and reports a year of delivery on its strategic goals. [read more]
Director Nominations Closing Date
Pacific Edge advises that its Annual Shareholder Meeting will be held on Thursday 27 July 2023 starting at 3pm. [read more]
Pacific Edge Full Year Result to be Announced 25 May 2023
Pacific Edge Limited advises that its full year results for the 12 months to 31 March 2023 (FY23) will be released on Thursday 25 May 2023, prior to 10am. [read more]
Pacific Edge Announces Key Activities at AUA 2023
Pacific Edge today announces its key activities at the 2023 AUA Annual meeting to be held April 28 – May 1 in Chicago, Illinois. [read more]
Pacific Edge Appoints Dr Tamer Aboushwareb Chief Medical Officer
Pacific Edge has promoted its VP of Medical Affairs Dr Tamer Aboushwareb into a new role as Chief Medical Officer. The appointment, which will see Dr Aboushwareb join Pacific Edge’s senior leadership team, is a recognition of the early impact the Medical Affairs Team has had on Pacific Edge’s market engagement in the USA. [read more]
Pacific Edge Appoints Danielle Gutter VP Sales, PEDUSA
Pacific Edge today announces the appointment of Danielle Gutter as its new Vice President of Sales, PEDUSA. Ms Gutter joined Pacific Edge Diagnostic USA (PEDUSA) on April 10th, 2023 and will head up Pacific Edge’s sales efforts for Cxbladder in the USA. [read more]
Quarterly Investor Update - Q4 23 Test Volumes Reach New Record
Pacific Edge has today released its Fourth Quarter Investor Update showing test volumes processed in its laboratories in Q4 23 increased to 8,878 tests, a 14% rise on the 7,768 tests in the prior quarter (Q3 23). [read more]
Pacific Edge Provides Update on Kaiser EMR Integration
Pacific Edge today announces it has completed the software development and integration testing on its project to integrate Cxbladder into the Electronic Medical Records (EMR) system of Kaiser Permanente. [read more]
Pacific Edge Appoints Glen Costin President APAC
Pacific Edge today announces the appointment of Glen Costin into the new role of President Asia Pacific (APAC) to realize the significant potential for the company’s genomic Cxbladder tests in the region. [read more]
Study Adds Support for Cxbladder Monitor Use in Cancer Surveillance
Pacific Edge today welcomes the release of new research supporting the clinical utility of the company’s genomic biomarker test Cxbladder Monitor in the surveillance for bladder cancer recurrence. [read more]
Pacific Edge to Showcase Leading Biomarker Strategies for the Evaluation and Management of Bladder Cancer at SESAUA
Pacific Edge today announces its key activities and highlights at the 87th Annual AUA Southeastern Section (SESAUA) meeting to be held March 15-18 in Amelia Island, Florida. [read more]
Pacific Edge Rings the Bell on Two Decades as an NZX Listed Company
Pacific Edge today rang the bell on two decades of its shares trading on the NZX Main Board. The ceremony was held at NZX’s offices in Auckland and was attended by Pacific Edge and NZX people, investors, analysts and the media. [read more]
Quarterly Investor Update - Q3 FY23 Test Volumes Rise 36% YOY
Pacific Edge has today released its Third Quarter Shareholder Update showing test volumes processed in its laboratories in the three months to the end of December 2022 increased 36% on the same three-month period a year ago. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.
